Hubro Therapeutics is pleased to announce regulatory approval in the UK for its phase 2 study with FMPV-1/GM-CSF in MSI-colorectal cancer.
Hubro Therapeutics is pleased to announce regulatory approval in the UK for its phase 2 study with FMPV-1/GM-CSF in MSI-colorectal cancer.
Stimulating the immune system to prevent cancer and improve the quality of the lives of high-risk families
Contact us
CEO Jon Amund Eriksen: jaeriksen@hubrobio.com